Reverse Payments Post Actavis: A Litigation Quagmire?

This article is part of a Chronicle. See more from this Chronicle

Keith Hylton, Jul 15, 2015

For the last decade or so, the FTC has had a bee in its bonnet over “reverse payment settlements.” Such a settlement occurs when a pioneer pharmaceutical firm terminates a patent infringement lawsuit against a generic drug maker by forming an agreement under which the generic enters the market at some later date (still before expiration of the patent) in exchange for a payment from the pioneer.

In th